Bio-Techne Corp.
TECHBio-Techne Corp. (TECH) is a global leader in the development, manufacturing, and distribution of biotechnology and pharmaceutical products. The company specializes in proteins, antibodies, and reagents used in scientific research, clinical diagnostics, and biopharmaceutical development. Founded in 1980, Bio-Techne serves customers across life sciences, healthcare, and biotech industries, providing innovative solutions to advance scientific discovery and improve healthcare outcomes.
Dividend History
| Pay Date | Amount | Ex-Date | Record Date |
|---|---|---|---|
| November 28, 2025 | $0.08 | 2025-11-17 | 2025-11-17 |
| August 29, 2025 | $0.08 | 2025-08-18 | 2025-08-18 |
| May 30, 2025 | $0.08 | 2025-05-19 | 2025-05-19 |
| February 28, 2025 | $0.08 | 2025-02-14 | 2025-02-17 |
| November 22, 2024 | $0.08 | 2024-11-08 | 2024-11-11 |
Dividends Summary
- Consistent Payer: Bio-Techne Corp. has rewarded shareholders with 69 dividend payments over the past 17 years.
- Total Returned Value: Investors who held TECH shares during this period received a total of $18.20 per share in dividend income.
- Latest Payout: The most recent dividend of $0.08/share was paid 56 days ago, on November 28, 2025.
- Yield & Schedule: TECH currently pays dividends quarterly with an annual yield of 0.46%.
- Dividend Growth: Since 2008, the dividend payout has decreased by 68.0%, from $0.25 to $0.08.
- Dividend Reliability: TECH has maintained or increased its dividend for 12 consecutive payments.
Company News
The Middle East exosomes market is projected to grow from USD 3.07 million in 2024 to USD 20.03 million by 2033, at a CAGR of 23.38%. Growth is driven by increasing adoption of exosome-based diagnostics and therapeutics, rising biomedical R&D investment, and growing demand for liquid biopsy technologies. Key challenges include stringent regulator...
Bio-Techne Corporation announced a quarterly dividend of $0.08 per share, payable on November 28, 2025, to shareholders of record on November 17, 2025. The global life sciences company generated over $1.2 billion in net sales in fiscal 2025.
MDxHealth has completed the acquisition of Exosome Diagnostics from Bio-Techne for $15 million, which includes the ExoDx Prostate test and related assets, with payments structured over four years.
RBC Capital upgraded Bio-Techne to Outperform, raising price target from $61 to $73, citing potential for mid-single-digit revenue growth and attractive valuation after recent market selloff.
The global recombinant human hair keratin protein market is experiencing rapid growth, driven by increasing demand in biomedical and cosmetic applications, with North America leading and Asia-Pacific showing the fastest growth potential by 2034.
